| May 2025

__________________________
______________________________
__________________________________

Al-Haya Medical Company 

P.O. Box 442, Riyadh 11411, Kingdom of Saudi Arabia
tel.: 96614655075; fax: 96614652354
www.alhaya-medical.com
e-mail: gm.sec@alhaya-medical.com
Mr. Khalid W. Kayyali

Business: Distributor of medicines, pharmaceutical and medical supplies.

Principal shareholders: Dr. Walid Kayyali & family.

Revenues: US$160,000.

Number of employees: 760.

Date established: 1967.

__________________________
______________________________
__________________________________

Astra Zeneca Latvija, Ltd. 

Skanstes Iela 13, B KO2P, Riga, LV1013, Latvia
tel.: 37067377100; fax: 37067377004
www.astrazeneca.com
e-mail: latvia@astrazeneca.com
Ms. Astruda Frudmane, Office Administrator

Business: Pharmaceuticals.

Principal shareholders: Astra Zeneca AB.

__________________________
______________________________
__________________________________

Brenntag India Pvt. Ltd. 

Phoenix House, B-Wing, Ground Floor, 462, Senapati Bapat Marg, Lower Parel (W), Mumbai 13, India
tel.: 912266637148; fax: 912224950473
www.brenntag.com
e-mail: Kamlesh.vora@ap.rhodia.com
Mr. Kamlesh Vora, Regional Business Manager

Business: Pharma.

__________________________
______________________________
__________________________________

Celyad

Rue Edouard Belin 2, 1435 Mont-Saint-Guibert, Brabant wallon, Belgium
www.celyad.com
e-mail: investors@celyad.com
tel.: 3210394100; fax: 3210394141
Mr. Filippo Petti, Chief Executive Officer

Business: Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer. Celyad is based in Mont-Saint-Guibert, Belgium, and New York, NY.

Listed stock exchange: Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.

Date established: 2007.

Number of employees: 100.

__________________________
______________________________
__________________________________

Dong-a 

252 Yongdudong Dongdaeniunku, Seoul, Korea
tel.: 8229208074; fax: 8229530336
www.donga.co.kr
e-mail: korpass@hanmatl.net
Mr. Shan Kook, Managing Director

Business: Pharmaceuticals.

__________________________
______________________________
__________________________________

Dr. August Wolff GmbH & Co.

Arzneimittel Sudbrackstrasse 56, 33611 Bielefeld, Germany
tel.: 495218808344; fax: 495218808100
www.wolff-arzneimittel.de
e-mail: hj.koehler@wolff-arzneimittel.de
Mr. Hans-Juergen Koehler, Head of Business Development

Business: Pharmaceuticals.

Principal shareholders: Wolff family.

Revenues: €57,000,000.

Capital: €12,300,000.

Number of employees: 325.

Date established: 1905.

__________________________
______________________________
__________________________________

Eriks Flexibles et Raccords

Route Departementale 910, 57420 Cheminot, France
tel.: 33387697989; fax: 33387697959
www.eriks.fr
e-mail: eriks.flexibles@eriks.fr
Mr. Julien Gauthier, Manager BU Hoses

Business: Industrial and hydraulic hoses; couplings.

Principal shareholders:

Eriks SAS
Decines (France).

Subsidiaries:

Vemoflex n.v.
LMC
BM Europe
Hydromeka (Belgium).

Date established: 1996.

Number of employees: 22.

__________________________
______________________________
__________________________________

Great Chemical Trading Co., Ltd.

1/59 Moo 7, Narkniwars Road, Latphrao, Bangkok 10230, Thailand
tel.: 6625394457; fax: 6625394458
e-mail: chuensai@loxinfo.co.th
Dr. Setachai Chuensaichol

Business: Import raw material and finished products for Thai FDA tenders.

__________________________
______________________________
__________________________________

Infectopharm GmbH 

Humboldtstrasse, D-64646 Heppenheim, Germany
tel.: 4962529640
Dr. Manfred Zoeller

Business: Development, production and distribution of pharmaceutical products. Specialization in anti-infectives (antibiotics, antivirals) mainly for the pediatrics profession.

News: Infectogrupp Inhal, worldwide the first spray (without fluorocarbons) of epinephrine (racepinephrin).

__________________________
______________________________
__________________________________

Inventiva

50 Rue de Dijon, 21121 Daix, France
www.inventivapharma.com
e-mail: info@inventivapharma.com
tel.: 33380447631; fax: 33380447561
Mr. Frédéric Cren, Chairman and Chief Executive Officer

Business: Inventiva is a clinical-stage biopharmaceutical company. Lanifibranor, its lead product candidate, is currently being evaluated in a NASH Phase IIb study. Inventiva is also developing odiparcil in a Phase IIa clinical trial for the treatment of patients with MPS, a group of rare genetic disorders. Two collaborations have also been put in place with AbbVie (phase I stage) and Boehringer Ingelheim (preclinical stage) entitling Inventiva to receive milestone payments and royalties. The Company employs more than >100 people and owns a library of ~240,000 molecules as well as an R&D facility.

Listed stock exchange: Compartment C of Euronext Paris.

__________________________
______________________________
__________________________________

IX Biopharma Ltd.

80 Robinson Road, #02-00, Singapore 068898
www.ixbiopharma.com
e-mail: info@ixbiopharma.com
tel.: 6562352270; fax: 6562352170
Lee Wei Hsiung, Secretary

Business: iX Biopharma Ltd. is a Singapore public-listed specialty pharmaceutical and nutraceutical company, operating a fully integrated business model from drug development and manufacturing to sales and marketing, with facilities in Australia. iX Biopharma Ltd. and its subsidiaries (the Group) focus on the development and commercialization of novel wafer formulations to improve the quality of life of those suffering from pain and other health conditions using its patented sublingual delivery technology, WaferiX. iX Biopharma Ltd.’s pipeline of products under development includes Wafermine, a sublingual Ketamine drug for the treatment of moderate to severe acute pain and depression, and Wafesil, a sublingual sildenafil drug, which has obtained approval and registration in Australia, for the treatment of male erectile dysfunction. iX Biopharma Ltd. has developed a medicinal cannabis drug using its WaferiX technology and is evaluating its use as a treatment for anxiety, tremor and inflammatory conditions. The Group’s nutraceuticals division, Entity Health Limited, is engaged in the development and commercialization of nutraceutical products that address specific conditions and improve quality of life. Entity Health Limited was launched on e-commerce in December 2017 and is now also stocked in pharmacies and health food stores across Australia.

Listed stock exchange: Singapore Exchange Limited.

Subsidiaries:

iX Biopharma Pty Ltd
iX Syrinx Pty Ltd
Entity Health Limited.

Date established: May 8, 2004.

Number of employees: 42.

News: http://www.ixbiopharma.com/news

__________________________
______________________________
__________________________________

Janssen – Cilag

Kft. 2045 Törökbálint, Tó Park, Hungary
tel.: 3623513858; fax: 3623510939
www.janssen-cilag.hu
e-mail: janssen@jnj.jnj.com
Ms. Maria Babgh, Communications Manager

Business: Prescription Pharmaceuticals.

Principal shareholders: Johnson & Johnson.

__________________________
______________________________
__________________________________

Krka, d.d., Novo mestoalia Group

Smarjeska Cesta 6 8501 Novo Mesto, Slovenia
www.krka.biz
e-mail: info@krka.biz
tel.: 38673312111; fax: 38673321537
Mr. Jože Colarič, President of the Management Board and Chief Executive

Business: The group manufactures and sells prescription and OTC drugs and veterinary medical products. It focuses on the development of proprietary generic drugs.

Listed stock exchange: Warsaw Stock Exchange. Ljubljana Stock Exchange.

Date established: 1954.

__________________________
______________________________
__________________________________

Malia Group

Sarraf Bldg., Zone Amaret Chaloub, P.O. Box 90201 Jdeidet-El-Metn, Lebanon
tel.: 9611888306; fax: 9611900100
www.maliagroup.com
e-mail: info@maliagroup.com
Mr. Jacques Jean Sarraf, Chairman

Business: Malia Group’s activities span across six leading sectors:

Industries (Pharmaceuticals & Personal Care)
Consumer Goods Distribution
Technology & Management Solutions
Fashion & Luxury
Contracting
Hospitality & Real Estate.

The Group is comprised of 25 companies (in Lebanon, Iraq, Syria, Algeria, Kuwait…) that have forged alliances with some of the world’s leading multinationals.

Principal shareholders:

Jacques Jean Sarraf
Ghazi Jean Sarraf
Nicole Semaan Sarraf
Maya Semaha Sarraf.

Subsidiaries:

Malia Holding
Malia Trust
Ch. Sarraf & Co.
Pharmaline
Pharmatrade
Cosmaline
Malia Moda
Malitab
MaliaTec
Malia Development
Lead Advertising
Natour Development
Malia Algerie
Malia Invest Holding
Hotelline Holding
Towerline Off-Shore
Capline Off-Shore
Leadline Off-Shore
Malia International Off-Shore
Mourakeb for Technical Services.

Date established: 1936.

Number of employees: 1,740.

__________________________
______________________________
__________________________________

Microbix Biosystems Inc.

265 Watline Avenue, Mississauga, Ontario L4Z 1P3, Canada
tel.: 19053618910; fax: 19053618911
www.microbix.com
e-mail: ir@microbix.com
Ms. Deborah Honig, Investor Relations

Business: Life science company and leading manufacturer of viral and bacterial antigens and reagents for the global diagnostics industry.

Listed stock exchanges: Toronto Stock Exchange (MBX).

Date established: 1988.

Number of employees: 70.

__________________________
______________________________
__________________________________

Neovacs

3-5 Impasse Reille, 75014 Paris, France
tel.: 33153109300; fax: 33153109303
www.neovacs.com
e-mail: cmasson@neovacs.com
Mr. Miguel Sieler, Chief Executive Officer

Business: Business: Néovacs has become a major player in the therapeutic vaccines for the treatment of autoimmune and/or inflammatory diseases. With its innovative technology inducing a polyclonal immune response, protected by four patent families potentially until 2032, Néovacs focuses its clinical efforts on the development of IFNa-Kinoid for treating lupus and dermatomyositis. The group also carries out preclinical work on other therapeutic vaccines to treat autoimmune diseases, cancer, allergies and type 1 diabetes.

Listed stock exchange: Euronext Paris.

__________________________
______________________________
__________________________________

Rhone Poulenc Rorer 

P.O. Box 23683, Dubai, United Arab Emirates
tel.: 9714318485; fax: 9714318598
Mr. Bassem Mehio, General Manager – Saudi Arabia & Gulf Region

Business: Pharmaceuticals.

Products:

Taxotere
Clexane/Levenox
Campto
Profenid
Flagyl.

__________________________
______________________________
__________________________________

Solco Basel Ltd. 

Soleliyo Establishment / Solco, P.O. Box 3542 Riyadh 11481, Kingdom of Saudi Arabia
tel.: 96614633172; fax: 96614632838
Dr. Khalid Khader, Country Manager

Business: Pharmaceuticals. Soleliyo Est. is the legal agent for a number of overseas pharmaceutical companies. Solco (a Swiss company) is one of them. Products include Disflaty, Solcoseryl, etc.

News: Solco markets and promotes these products in Saudi Arabia.

__________________________
______________________________
__________________________________

Sued Farmaceutica, C. Por A. 

Avenida Maximo Gomez No. 27, P.O. Box 847, Santo Domingo, Dominican Republic
tel.: 18096824344; fax: 18096861010
e-mail: sufarca@tricom.net
Mr. Luis Sued

Business:

Distributors of pharmaceuticals and diagnostics
Manufacturer (Laboratorios Sued, S.A.) of pharmaceuticals.

__________________________
______________________________
__________________________________

Uni-drive Systems (S) Pte Ltd.

19 Pioneer Sector 2, Singapore 628379
tel.: 6568612340; fax: 6568610403; mobile: 6594555912
www.uni-drive.com
e-mail: unidrive@singnet.com.sg
Mr. Bernard Neo, General Manager

Business: Established in the year 1987, Uni-drive Systems (S) Pte Ltd. set out to grow a business specializing in Mechanical Power Transmissions. Over the 30 years, the company has grown and now boosts a business that covers many countries and has established a sales distribution network throughout Asia. The company has become a one-stop-shop for all aspects of industrial Mechanical Power Transmission products such as Pulley, Beltings, Coupling, Bearings, Gears, Pump & Spares, Fans and all kinds of engineering work including Servicing, Fabrication, Turnkey Projects, Installation and much more. The company provides customers with full plant bearing and power transmission survey, application advice and shut down support; 24 hours, 7 days. Uni-drive not only manufactures its own house in-brand “UNI-DRIVE” products, it also represents many leading renowned manufacturers from USA, Germany, U.K., Japan, Holland and Korea; catering to the requirements of the Electronics, Oil & Gas, Pharmaceutical, Power Generation and Marine industries. With a strong global sourcing network, a team of youthful, dedicated, dynamic and well-equipped staff and close partnership with its established suppliers, the company can deliver high quality products. Together with placing its valued customers’ interests and satisfaction as its top priority, Uni-drive is committed to quality, reliability and on-time delivery with a very comprehensive range of ready Ex-stock products built over the years and competitive pricing to meet all needs.

Date established: 1987.

Number of employees: 30.

__________________________
______________________________
__________________________________

Valneva

8 Rue Alain Bombard, 44800 Saint-Herblain, France
www.valneva.com
e-mail: investors@valneva.com
tel.: 33228073710
Mr. Thomas Lingelbach, CEO

Business: Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and has leveraged its expertise and capabilities both to successfully commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against the chikungunya virus and Lyme disease.

Listed stock exchange: Euronext Paris; NASDAQ (VALN).

__________________________
______________________________
__________________________________

Vassos Eliades Ltd.

24 Aristidou Str., 2370 Ayios Dometios, P.O. Box 21085, 1501 Nicosia, Cyprus
tel.: 35722897300
www.vassoseliades.com
Mr. Dinos Charalambous, Logistic Manager

Business: Vassos Eliades Ltd is one of the biggest trading companies in Cyprus. Its main activities are the importation, sale and distribution of consumer goods through all the trade channels of the market. The range of products distributed is wide, ranging from foodstuffs, alcoholic beverages, mass market consumer goods, luxury watches, jewelry and accessories as well as fitness equipment. Vassos Eliades Ltd is trusted by the largest multinational companies in the world to handle their brands in the Cyprus market and has been the agent of Swiss food giant NESTLE for the island of Cyprus since the inception of the company in 1933.

Principal shareholders:

Mr. George Eliades
Mr. Kypros Eliades.

Date established: 1933.

Number of employees: 290.

__________________________
______________________________
__________________________________